S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:ALDX

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

$4.07
-0.15 (-3.55%)
(As of 03/4/2024 ET)
Today's Range
$3.99
$4.29
50-Day Range
$3.00
$4.22
52-Week Range
$1.42
$11.97
Volume
608,908 shs
Average Volume
505,423 shs
Market Capitalization
$239.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33

Aldeyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
203.0% Upside
$12.33 Price Target
Short Interest
Healthy
3.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.76) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.76 out of 5 stars

Medical Sector

483rd out of 960 stocks

Pharmaceutical Preparations Industry

226th out of 440 stocks


ALDX stock logo

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

ALDX Stock Price History

ALDX Stock News Headlines

Intellia Therapeutics, Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
BTIG Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)
Aldeyra stock jumps 8% on dermatitis drug updates
Lexington biotech gets second FDA rejection this year
What's Going On With Aldeyra Therapeutics Stock?
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
See More Headlines
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
3/04/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.33
High Stock Price Target
$15.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+203.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-62,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.58 per share

Miscellaneous

Free Float
54,528,000
Market Cap
$239.40 million
Optionable
Optionable
Beta
1.53
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report














ALDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALDX shares.
View ALDX analyst ratings
or view top-rated stocks.

What is Aldeyra Therapeutics' stock price target for 2024?

3 analysts have issued 1-year target prices for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $15.00. On average, they anticipate the company's share price to reach $12.33 in the next twelve months. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for ALDX
or view top-rated stocks among Wall Street analysts.

How have ALDX shares performed in 2024?

Aldeyra Therapeutics' stock was trading at $3.51 at the start of the year. Since then, ALDX shares have increased by 16.0% and is now trading at $4.07.
View the best growth stocks for 2024 here
.

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ALDX earnings forecast
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. During the same quarter in the prior year, the business earned ($0.23) earnings per share.

What ETF holds Aldeyra Therapeutics' stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (14.61%), Vanguard Group Inc. (6.68%), Verition Fund Management LLC (2.25%), Dimensional Fund Advisors LP (1.77%), Eagle Asset Management Inc. (1.72%) and Northern Trust Corp (0.67%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady.
View institutional ownership trends
.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALDX) was last updated on 3/5/2024 by MarketBeat.com Staff